Following this activity, participants should be able to: (1) Describe the general approach to treatment for pediatric high-grade gliomas (pHGG). (2) Identify pertinent biomarkers and molecular alterations that impact the stratification and treatment of pHGG. (3) Summarize the relevant data for targeted therapy and discuss potential agents in the pipeline in the treatment for pHGG.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95889
- Start Date: 2024-09-10 05:00:00
- End Date: 2024-09-10 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Menarini-Stemline - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest